Skip to main content

Advertisement

SpringerLink
Log in

Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Colon cancer is one of the leading causes of cancer-related deaths worldwide. The increased incidence of comorbid diseases in elderly patients above 70 leads to the need of less aggressive strategies to be used in the adjuvant setting of stage III colon cancer.

Method

Our prospective cohort study was performed in the period from April 2017 to March 2020. Seventy-five patients with newly diagnosed stage III colon cancer received adjuvant chemotherapy after surgery. Patients who either received adjuvant chemotherapy less than 3 months due to intolerability or toxicity from medications or who have more than one type of cancers or metastatic disease from the start were excluded from the study. Patients’ clinicopathological characteristics in relation to oxaliplatin- and non-oxaliplatin-based chemotherapeutic regimens were analyzed with survival assessment.

Results

In our study, patients above 70 had better overall survival (OS) in the non-oxaliplatin chemotherapy group (p-value = 0.032) in contrast to OS in patients under 70 which was better in the oxaliplatin group (p-value < 0.001). By comparing the OS between the two age groups, the OS was better in patients < 70 years (p-value = 0.001). Additionally, we found that the DFS in patients above 70 was better in oxaliplatin-based regimens than in the non-oxaliplatin group (p-value = 0.011) with better survival rates (81.8% vs 15.7%), and markedly high DFS in patients under 70 for oxaliplatin based regimens (p-value < 0.001), with survival rates (31.1% vs 0%). By comparing the DFS between the two age groups, the DFS was better in patients < 70 years (p-value < 0.001). The disease recurrence was in favor of the non-oxaliplatin group with significant p-value = 0.003, while mortality occurred more in the oxaliplatin group (p-value < 0.001).

Conclusions

The appropriate selection of a personalized strategy for treatment of stage III colon cancer plays an important role in the outcome of the disease. Our findings supported the use of oxaliplatin-based chemotherapy as a standard treatment option in the adjuvant management of stage III colon cancer patients in all age groups. The benefit of non-oxaliplatin-based chemotherapy was limited to patients above 70 which might be an effective option for elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kassem N, Sharaf S, Abdel Aziz A, Mohsen M, Kassem H, El Khateeb S, Medhat N, Nagdy B, Abdel Moneim R, Abdulla M. Towards validation of targeted next-generation sequencing on formalin fixed paraffin embedded colorectal cancer tissues in Egyptian population: a pilot study with feasibility and challenges. Int J Cancer Tremnt. 2018;1(1):20–9.

    Google Scholar 

  2. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16. https://doi.org/10.1200/JCO.2008.20.6771.

    Article  CAS  PubMed  Google Scholar 

  3. Chau I, Cunningham D. Adjuvant therapy in colon cancer—what when and how? Ann Oncol. 2006;17:1347–59.

    Article  CAS  Google Scholar 

  4. Wu X, Chen VW, Andrews PA, Chen L, Hsieh M, Fontham ET. Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. J La State Med Soc. 2004;156:255–61.

    PubMed  Google Scholar 

  5. Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018;25:1454–5. https://doi.org/10.1245/s10434-018-6462-1.

    Article  PubMed  Google Scholar 

  6. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.

    Article  Google Scholar 

  7. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol. 2007;25:102–9.

    Article  CAS  Google Scholar 

  8. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71. https://doi.org/10.1200/JCO.2010.33.6297.

    Article  CAS  PubMed  Google Scholar 

  9. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Phase III study of fluorouracil leucovorin and levamisole in high risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8.

    Article  Google Scholar 

  10. Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.

    Article  CAS  Google Scholar 

  11. Holleczek B, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2158–68.

    Article  Google Scholar 

  12. Van Cutsem E, Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis adjuvant treatment and follow-up. Ann Oncol. 2009;20(suppl 4):49–50.

    Article  Google Scholar 

  13. Bergquist JR, et al. Benefit of postresection adjuvant chemotherapy for stage III colon cancer in octogenarians: analysis of the National Cancer Database. Dis Colon Rectum. 2016;59:1142–9.

    Article  Google Scholar 

  14. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–76.

    Article  CAS  Google Scholar 

  15. Lund CM, Nielsen D, Dehlendorff C, Christiansen AB, Rønholt F, Johansen JS, Vistisen KK. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open. 2016;1: e000087. https://doi.org/10.1136/esmoopen-2016-000087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lin HS, Turner DJ, Srivastava A, Jameson MB. The benefit and tolerability of adjuvant chemotherapy in elderly stage III colon cancer patients: a 3 year retrospective audit. J Gerontol Geriatr Res. 2016;5:4. https://doi.org/10.4172/2167-7182.1000318.

    Article  Google Scholar 

  17. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.

    Article  CAS  Google Scholar 

  18. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease-free survival (DFS). J Clin Oncol. 2010;28(15_suppl):3521–3521.

  19. Haller DG, O’Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmol HJ. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized controlled trials. Ann Oncol. 2015;26:715–24. https://doi.org/10.1093/annonc/mdv003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients ( pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol. 2009;27(15_suppl):4010.

  21. Lu CS, Chang PY, Chen YG, Chen JH, Wu YY, Ho CL. Stage III colon cancer: the individualized strategy of adjuvant chemotherapy for aged under and over 70. PLoS ONE. 2015;10(9): e0138632. https://doi.org/10.1371/journal.pone.0138632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kane RL, Shamliyan T, Talley K, Pacala J. The association between geriatric syndromes and survival. J Am Geriatr Soc. 2012;60:896–904.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Heba F. Taha

  2. Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Ola A. Harb

  3. General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Loay M. Gertallah

  4. Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Lobna A. Abdelaziz

Authors
  1. Heba F. Taha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ola A. Harb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Loay M. Gertallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lobna A. Abdelaziz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heba F. Taha.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taha, H.F., Harb, O.A., Gertallah, L.M. et al. Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years. J Gastrointest Canc 53, 581–591 (2022). https://doi.org/10.1007/s12029-021-00666-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00666-2

Keywords

Search

Navigation